tradmap

AVLN Earnings Avalyn Pharma Inc.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated

Quarterly results

Diluted EPS (quarterly)
-$63 -$32 $0 Q1 '25 Q2 '25 Q1 '26 Q2 '26
EPS
Net income (quarterly)
-$29M -$14M $0 Q1 '25 Q2 '25 Q1 '26 Q2 '26
Net income
Return on equity (quarterly)
-7% 2% 10% 0% Q1 '25 Q2 '25 Q1 '26 Q2 '26
ROE

Reported EPS history

1–4 of 4
Q2 20262026-06-30-3.602026-08-1210-Q
Q1 20262026-03-31-21.832026-06-0310-Q
Q2 20262025-06-30-52.832026-08-1210-Q
Q1 20262025-03-31-63.242026-06-0310-Q

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.